Regulatory Affairs Services Provider in Finland
DDReg provides regulatory affairs services in Finland for pharmaceutical, medical device, and biologics companies. Our RA consultants manage Fimea marketing authorisation submissions across national, mutual recognition, decentralised, and centralised procedures; coordinate HILA reimbursement and wholesale price applications; manage Vnr Nordic article number registrations; and maintain post-authorisation compliance across Finland's national health insurance system.
Finland's Regulatory Framework for Medicines and Medical Devices
The Finnish Medicines Agency (Fimea; Swedish: Säkerhets- och utvecklingscentret för läkemedelsområdet) is the national competent authority for regulating pharmaceuticals and medical devices in Finland. Established in 2009 as successor to the National Agency for Medicines, Fimea operates as a central administrative agency under the Ministry of Social Affairs and Health. Its headquarters are in Kuopio, with additional offices in Helsinki, Turku, Tampere, and Oulu. Fimea holds authority over marketing authorisations, GMP and GDP inspections, pharmacovigilance services, clinical trial authorisation, blood and tissue establishment oversight, and biobank regulation.
The primary legislative basis is the Medicines Act (395/1987) and Medicines Decree (693/1987), supplemented by Fimea regulations and guidance. Medical devices are governed by the Finnish Medical Devices Act (719/2021), implementing EU MDR 2017/745 and IVDR 2017/746 into Finnish law. Reimbursement and pricing fall under the Health Insurance Act (1224/2004) and Council of State Decree on the price list for drugs (713/2013). Licence decisions are issued in Finnish or Swedish, Finland's two official languages, although applications may be submitted in English.
Finland participates actively in EU network procedures. Fimea contributes scientific assessors to EMA committees including CHMP, PRAC, and CVMP. Fimea serves as Reference Member State (RMS) in mutual recognition and decentralised procedures and cooperates bilaterally with Nordic medicines agencies, the Swedish MPA, Danish DKMA, Norwegian NoMA, and Icelandic IMA through joint assessments and working group participation. Fimea produces health technology assessments (HTA) of new hospital medicines, published as Fimea assessment reports; COHERE Finland uses these reports as the basis for national recommendations on hospital product procurement.
Regulatory and Market Access Authorities in Finland
| Authority / Body | Role |
|---|---|
| Fimea (Finnish Medicines Agency) | National competent authority; grants marketing authorisations; conducts GMP/GDP inspections; oversees pharmacovigilance and clinical trials; supervises medical devices and pharmaceutical operators; produces hospital medicine HTA assessments |
| HILA (Pharmaceuticals Pricing Board) | Subordinate body of Ministry of Social Affairs and Health; confirms reimbursement status and approved maximum wholesale price for medicinal products under the Health Insurance Act (1224/2004); administers all three reimbursement tiers |
| Kela (Social Insurance Institution of Finland) | Administers the national health insurance scheme; processes reimbursements at pharmacy point-of-sale; maintains the ePrescription database (KanTa); oversees the reference price system; receives quarterly price notifications for substitutable products |
| COHERE Finland (Council for Choices in Health Care in Finland) | Provides national recommendations on hospital medicine use; decisions based on Fimea HTA reports; hospital districts procure through competitive tendering under the Act on Public Contracts (1397/2016) |
| PIC (Pharmaceutical Information Centre) | Allocates and administers Vnr Nordic article numbers for Finland; distributes product and pricing information to Fimea, Kela, HILA, pharmacies, hospital pharmacies, and wholesalers via the Vnr extranet service |
Regulatory Consulting in Finland - Services Portfolio
DDReg's regulatory services in Finland cover the full product lifecycle across medicines, medical devices, biologics, and advanced therapies.
-
Marketing Authorisation - Pharmaceuticals
-
FIMEA Registration Services Finland - Pricing and Reimbursement
-
Vnr Nordic Article Number Management
-
Medical Devices and IVDs
-
Clinical Trials
-
Post-Authorisation Lifecycle Management
Regulatory Affairs Process in Finland Regulatory Approval Timelines
DDReg manages Finnish regulatory submissions through structured phases:
-
Pre-Submission Strategy
-
Dossier Preparation
-
Fimea Scientific Assessment
-
Marketing Authorisation and Vnr Registration
-
HILA Reimbursement and Post-Authorisation Compliance
Finland Regulatory Approval Timelines
Assessment timelines follow EU regulatory framework standards. Clock stops for applicant responses are excluded from the active assessment period:
| Procedure | Assessment Period |
|---|---|
| National Procedure (pharmaceuticals) | 210 days (excl. clock stops) |
| Mutual Recognition Procedure - RMS phase | 90 days |
| Mutual Recognition Procedure - CMS phase | 90 days |
| Decentralised Procedure (DCP) | 210 days (RMS + CMS combined) |
| Centralised Procedure (EMA) | 210 days (CHMP opinion) |
| Type IA variation | 30 days (notification) |
| Type IB variation | 30 days (assessment) |
| Type II variation | 60 days (up to 90 days with extension) |
| HILA reimbursement decision | 180 days from complete application (statutory) |
| Vnr allocation (new product) | Allocated before market entry; 8 working-day advance notification deadline for product information |
| Medical device (CE marked) - Fimea oversight | No prior Fimea authorisation required; surveillance post-market |
Note: Clock stop periods for question list responses extend calendar timelines. HILA reimbursement and Fimea authorisation run as separate sequential processes. Vnr registration and Kela ePrescription database entry are required before commercial pharmacy supply can begin.
Nordic Regulatory Affairs Services - DDReg's Expertise in Finland
DDReg understands Fimea's scientific assessment standards, RMS procedure management capabilities, and Informal Regulatory Guidance service. Our team coordinates pre-submission guidance requests, prepares complete submissions for Fimea validation, and manages clock-stop response packages. For programmes where Fimea's Nordic network relationships offer assessment advantages, DDReg assesses whether Finland RMS selection is appropriate.
EU procedure dossiers submit in English. Module 1 national documents SmPC, PIL, and labelling require both Finnish and Swedish before market placement in Finland, reflecting Finland's bilingual official language status. Fimea issues all licence decisions in Finnish or Swedish. DDReg provides regulatory writing in both Finnish and Swedish for Module 1 national documents, Vnr notifications, and Fimea correspondence.
Fimea marketing authorisation and HILA reimbursement are separate processes. For most Rx products, HILA inclusion and Kela reimbursement at pharmacy are essential to commercial viability patients pay full price for non-reimbursed prescription medicines. DDReg coordinates Fimea and HILA submission timelines in parallel, prepares health economic documentation for reimbursement tier assessment, and manages Kela quarterly price notifications through the Vnr extranet service.
The Vnr Nordic article number system is a Finland-specific infrastructure requirement that connects product identity to the Kela ePrescription database, pharmacy dispensing systems, and hospital pharmacy supply chains. DDReg manages Vnr allocation through PIC, submits Vnr extranet notifications within the eight-working-day deadline window, and coordinates product launch, price change, and market withdrawal notifications to all downstream recipients Fimea, Kela, HILA, Oriola, Tamro, Magnum Medical, and the Association of Finnish Pharmacies.
The 'Nordic regulatory affairs services' reflects a commercial reality: companies entering Scandinavia typically seek coordinated regulatory strategies across Finland, Sweden, Denmark, and Norway rather than isolated national submissions. DDReg designs multi-country Nordic submission programmes, assesses where MRP or DCP procedures with Finland, Sweden, or Denmark as RMS offer timeline or scientific advantages, and coordinates parallel HILA, TLV, and DKMA-Amgros reimbursement strategies.
Global Reach Explorer
Find Your Solution
Our Regulatory Affairs Consulting Services in Finland portfolio covers:
Regulatory Strategies
The pharmaceutical industry operates under stringent regulations to ensure the safety, efficacy, and quality...
New Product Marketing Authorizations
Navigating marketing authorization is a complex and time-sensitive process. Every country has its own regulatory framework...
Gap Analysis and Remediation
In the highly regulated pharmaceutical industry, maintaining compliance is critical. Regulatory gap analysis helps identify deficiencies in technical documentation...
Regulatory Due Diligence
Regulatory issues arise unexpectedly and can create significant strain on a company’s resources. As such, it is advisable for all companies to carry out regular and frequent regulatory due diligence and audits...
API & DMF services
Drug Master Files (DMFs) contain confidential and detailed information regarding API processes—from manufacturing to storage. DDReg’s DMF Services deliver precise...
CMC Advisory
DDReg’s CMC services are dedicated to assisting customers in developing robust and an efficient regulatory strategy through all development phases - authoring...
Post Approval Life Cycle Management
Maximize product value with expert pharma lifecycle management. Our dedicated team ensures that your product remains on shelves and compliant with ever-evolving regulations through strategic post-approval management...
Certification Services
Partner with DDReg to navigate the complex process of regulatory certification of pharmaceutical...
ANDA and MA Holder Services
Our comprehensive services support both Abbreviated New Drug Applications (ANDA) and Marketing Authorization processes.
Publishing & Submission
Our comprehensive digital solution transforms traditional paper dossier submissions into a streamlined electronic format. With robust infrastructure and cutting‐edge management processes...
